Cholinesterase and acetylcholinesterase inhibition has shown potential in reducing neurodegenerative effects in patients with AD (Sharma, 2019), which likewise encourages the development of new cholinesterase inhibitors, since current agents may cause several side effects. The gene discussed is ACHE; the disease is Alzheimer disease.